"Preclinical Science & New Treatments in Psychiatry: A Three-Act Play"
Charles Zorumski, MD
Samuel B. Guze Professor of Psychiatry
Professor of Neuroscience
Director of the Taylor Family Institute for Innovative Psychiatric Research
Co-Director of the Silvio O. Conte Neuroscience Center
Washington University-St. Louis School of Medicine
This talk will discuss pathways to new treatments in psychiatry focusing on the role of preclinical neuroscience in the development of neurosteroids and oxysterols. The talk will also discuss repurposing of an approved drug, nitrous oxide, for major depression, and repurposing of a psychiatric medication, fluvoxamine, for COVID-19.
Objectives
The activity is designed to help the learner
- Discuss pathways to new treatments in psychiatry including the role of preclinical neuroscience in treatment development
- Describe the current state of neurosteroids and oxysterols as treatments in psychiatry
- Describe the role of repurposing of existing treatments as new therapies in psychiatry and the role of repurposing current psychiatric treatments for medical and neurological illnesses
Sponsored by the Luton Lecture Fund Department of Psychiatry and Behavioral Sciences and Vanderbilt Brain Institute. This educational activity received no commercial support.